Magnolia Medical closes $13.8M Series B to commercialize blood collection system

SteriPath system--Courtesy of Magnolia Medical Technologies

Magnolia Medical Technologies raised a $13.8 million Series B to ramp up the commercialization of its flagship blood-collection system. It is the only device on the market that eradicates false-positive blood cultures, which can lead to unnecessary treatment.

Blood cultures are used to diagnose septicemia, a potentially life-threatening consequence of bloodstream infection. But with an average of 1.2 million false-positive blood cultures taken each year, the U.S. healthcare system spends an excess of $4 billion annually on unnecessary treatment for false sepsis cases.

"In today's hospital environment, new technologies and products must significantly improve patient safety and outcomes while driving substantial cost savings," said Dr. Garheng Kong of HealthQuest Capital, which led the round, in the statement. "The commercial traction Magnolia Medical has demonstrated affirms that SteriPath delivers on both of these requirements. We look forward to working with Magnolia Medical's team to advance SteriPath's commercial success as well as continue to broaden the company's product and intellectual property portfolio, both of which are quite substantial at this stage of the company's development."


Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

The SteriPath system is a vacuum-assisted blood collection system delivered in a sterile, single-use package. The self-contained system removes multiple opportunities for the sample to be contaminated, for example, during preparation, assembly or while puncturing the vein to take the sample.

In addition to accelerating its commercialization efforts, the funding will also be used to support Magnolia Medical’s ongoing development of devices to cut down on human errors that can lead to false-positive and false-negative test results.

- here's the statement

Related Articles:
Canadian microcap starts PMA submission for novel sepsis device
EarlySense launches patient monitoring tech to detect sepsis in non-ICU patients
Harvard's Wyss launches Opsonix, backed by Baxter in $8M round to get sepsis device into clinic
T2 Biosystems wins FDA approval for sepsis diagnostic system

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.